ANAB
Price
$22.54
Change
-$1.15 (-4.85%)
Updated
Aug 6 closing price
Capitalization
662.24M
4 days until earnings call
QTTB
Price
$1.91
Change
-$0.04 (-2.05%)
Updated
Aug 7, 10:44 AM (EDT)
Capitalization
23.79M
Interact to see
Advertisement

ANAB vs QTTB

Header iconANAB vs QTTB Comparison
Open Charts ANAB vs QTTBBanner chart's image
AnaptysBio
Price$22.54
Change-$1.15 (-4.85%)
Volume$474.19K
Capitalization662.24M
Q32 Bio
Price$1.91
Change-$0.04 (-2.05%)
Volume$8.1K
Capitalization23.79M
ANAB vs QTTB Comparison Chart in %
Loading...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QTTB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANAB vs. QTTB commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a StrongBuy and QTTB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (ANAB: $22.54 vs. QTTB: $1.95)
Brand notoriety: ANAB and QTTB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 81% vs. QTTB: 9%
Market capitalization -- ANAB: $662.24M vs. QTTB: $23.79M
ANAB [@Biotechnology] is valued at $662.24M. QTTB’s [@Biotechnology] market capitalization is $23.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $210.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 0 FA rating(s) are green whileQTTB’s FA Score has 0 green FA rating(s).

  • ANAB’s FA Score: 0 green, 5 red.
  • QTTB’s FA Score: 0 green, 5 red.
According to our system of comparison, QTTB is a better buy in the long-term than ANAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 6 TA indicator(s) are bullish while QTTB’s TA Score has 4 bullish TA indicator(s).

  • ANAB’s TA Score: 6 bullish, 4 bearish.
  • QTTB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ANAB is a better buy in the short-term than QTTB.

Price Growth

ANAB (@Biotechnology) experienced а -9.77% price change this week, while QTTB (@Biotechnology) price change was -5.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +9.93%, and the average quarterly price growth was +14.10%.

Reported Earning Dates

ANAB is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($662M) has a higher market cap than QTTB($23.8M). ANAB YTD gains are higher at: 70.242 vs. QTTB (-43.314). QTTB has higher annual earnings (EBITDA): -40.39M vs. ANAB (-76.35M). ANAB has more cash in the bank: 340M vs. QTTB (65.5M). ANAB has less debt than QTTB: ANAB (15.6M) vs QTTB (18.8M). ANAB has higher revenues than QTTB: ANAB (112M) vs QTTB (0).
ANABQTTBANAB / QTTB
Capitalization662M23.8M2,782%
EBITDA-76.35M-40.39M189%
Gain YTD70.242-43.314-162%
P/E RatioN/AN/A-
Revenue112M0-
Total Cash340M65.5M519%
Total Debt15.6M18.8M83%
FUNDAMENTALS RATINGS
ANAB vs QTTB: Fundamental Ratings
ANAB
QTTB
OUTLOOK RATING
1..100
6893
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
46
Fair valued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4651
P/E GROWTH RATING
1..100
77100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QTTB's Valuation (46) in the null industry is somewhat better than the same rating for ANAB (86) in the Biotechnology industry. This means that QTTB’s stock grew somewhat faster than ANAB’s over the last 12 months.

ANAB's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that ANAB’s stock grew similarly to QTTB’s over the last 12 months.

ANAB's SMR Rating (100) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that ANAB’s stock grew similarly to QTTB’s over the last 12 months.

ANAB's Price Growth Rating (46) in the Biotechnology industry is in the same range as QTTB (51) in the null industry. This means that ANAB’s stock grew similarly to QTTB’s over the last 12 months.

ANAB's P/E Growth Rating (77) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that ANAB’s stock grew similarly to QTTB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABQTTB
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 16 days ago
78%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QTTB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARTIX35.300.27
+0.77%
Artisan International Investor
GCVCX23.63N/A
N/A
Goldman Sachs Large Cp Val Insghts C
BMCCX18.39N/A
N/A
BlackRock Advantage Large Cap Gr Inv C
MSDOX13.80N/A
N/A
Morgan Stanley Emerging Mkt ex China C
RLISX24.25-0.02
-0.08%
Russell Inv Equity Income S

ANAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with CLRB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
-4.85%
CLRB - ANAB
40%
Loosely correlated
-1.85%
QTTB - ANAB
39%
Loosely correlated
-1.52%
ADCT - ANAB
39%
Loosely correlated
-4.35%
AMRN - ANAB
38%
Loosely correlated
-0.53%
HRMY - ANAB
36%
Loosely correlated
-0.77%
More

QTTB and

Correlation & Price change

A.I.dvisor indicates that over the last year, QTTB has been closely correlated with CLRB. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if QTTB jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QTTB
1D Price
Change %
QTTB100%
-1.52%
CLRB - QTTB
66%
Closely correlated
-1.85%
MESO - QTTB
51%
Loosely correlated
+0.45%
STOK - QTTB
49%
Loosely correlated
+1.62%
ADCT - QTTB
46%
Loosely correlated
-4.35%
ANAB - QTTB
40%
Loosely correlated
-4.85%
More